

Florida MEDS-AD Waiver

**Quarterly Progress Report
October 1, 2014 – December 31, 2014**

**1115 Research and
Demonstration Waiver
#11-W-00205/4**



This page intentionally left blank

Table of Contents

I. Introduction.....	1
II. Budget Neutrality Update	1
III. Operational Update	2
1. Eligibility and Enrollment	2
2. Comprehensive Medication Reviews	3
3. Data Mining Activities	3
IV. Evaluation Activity	4
1. Evaluation Requirements	4
2. MEDS-AD MTM Program Description, Design, and Initial Findings	4
3. Medicaid Fraud Control Unit Evaluation Component.....	4
V. Waiver History.....	5
1. Legislative Changes	5
2. Program Design	5
3. Waiver Extension or Phase-Out	6
4. Maintenance of Effort (MOE) Provisions in Section 1902(a)(74) and 1902(gg).....	6
Attachment A Case Review Activity Report.....	7
Attachment B Temporary Extension	8

List of Tables

Table 1 Budget Neutrality	1
Table 2 MEDS-AD Waiver Enrollment.....	3

This page intentionally left blank

I. Introduction

This report includes programmatic and financial activities for the period October 1, 2014, through December 31, 2014. By implementing Florida's 1115 MEDS-AD Waiver (MEDS-AD Waiver), the Agency for Health Care Administration (Agency) seeks to demonstrate that the total cost of providing access to care for the MEDS-AD population (including costs for the Medication Therapy Management (MTM) program) will not exceed expected long-term cost of care for these individuals had they not received coverage until they required institutional care.

II. Budget Neutrality Update

The following table compares actual MEDS-AD Waiver expenditures to the costs projected for this population had the MEDS-AD Waiver not been granted. To date, actual expenditures have been below the projected cost.

Table 1 Budget Neutrality MEDS-AD Waiver							
Demo Year	Quarter Ended	WW Expenditures (\$)	WW Expenditures Cumulative Total (\$)	WOW (Target) Expenditures (\$)	WOW Expend Total (\$)	Difference (\$)	Cumulative Difference (\$)
DY1	Q1	51,696,950		507,710,894		456,013,944	
	Q2	132,235,096		507,710,894		375,475,798	
	Q3	105,271,113		507,710,894		402,439,781	
	Q4	146,356,839	435,559,998	507,710,894	2,030,843,575	361,354,055	1,595,283,577
DY2	Q5	69,927,763		460,700,626		390,772,863	
	Q6	79,047,475		460,700,626		381,653,151	
	Q7	87,567,517		460,700,626		373,133,109	
	Q8	90,210,963	762,313,716	460,700,626	3,873,646,079	370,489,663	3,111,332,363
DY3	Q9	93,882,619		455,999,599		362,116,980	
	Q10	103,108,178		455,999,599		352,891,421	
	Q11	95,761,142		455,999,599		360,238,457	
	Q12	96,128,169	1,151,193,824	455,999,599	5,697,644,476	359,871,430	4,546,450,652
DY4	Q13	107,727,900		465,401,653		357,673,753	
	Q14	106,365,677		465,401,653		359,035,976	
	Q15	120,849,499		465,401,653		344,552,154	
	Q16	133,665,863	1,619,802,762	465,401,653	7,559,251,086	331,735,790	5,939,448,324
DY5	Q17	138,153,082		460,700,626		322,547,544	
	Q18	144,229,555		460,700,626		316,471,071	
	Q19	134,966,909		460,700,626		325,733,717	
	Q20	148,599,566	2,185,751,874	460,700,626	9,402,053,590	312,101,060	7,216,301,716
DY6	Q21	154,004,876		*			
	Q22	146,340,361		*			
	Q23	155,268,617		*			

Table 1 Budget Neutrality MEDS-AD Waiver							
Demo Year	Quarter Ended	WW Expenditures (\$)	WW Expenditures Cumulative Total (\$)	WOW (Target) Expenditures (\$)	WOW Expend Total (\$)	Difference (\$)	Cumulative Difference (\$)
	Q24	163,774,246	2,805,139,974	*	9,402,053,590		6,596,913,616
DY7	Q25	165,396,338		*			
	Q26	184,629,761		*			
	Q27	165,063,579		*			
	Q28	168,922,270	3,489,151,922	*	9,402,053,590		5,912,901,668
DY8	Q29	151,084,893		*			
	Q30	150,685,372		*			
	Q31	159,542,998		*			
	Q32	162,697,430	4,113,162,615	*	9,402,053,590		5,123,996,918
DY9	Q33	158,788,398		*			
	Q34	78,648,234	4,350,599,249	*	9,402,053,590		5,051,454,340
	Q35	56,437,124	4,405,129,161	*	9,402,053,590		4,996,924,429
	Q36	116,880,369	4,522,009,530	*	9,402,053,590		4,880,044,060

*The original WOW expenditure ceiling was not increased with the renewal period beginning in Quarter 21. The \$7,216,301,716 cumulative difference between the approved budget neutrality ceiling and actual waiver expenditures as of the end of the original demonstration period on December 31, 2010, was allocated across the 12 renewal quarters as the new expenditure ceiling.

III. Operational Update

1. Eligibility and Enrollment

The Florida Department of Children and Families is responsible for conducting intake, assessment, eligibility determination, enrollment, disenrollment, and data collection on the availability of third-party coverage, including Medicare, and annual re-determinations of eligibility.

To be eligible for the MEDS-AD Waiver, recipients must be at or below 88% of the federal poverty level (FPL) with assets at or below \$5,000 for an individual (\$6,000 for a couple) and be in one of the following Medicaid eligibility groups (MEGs):

- **MEG 1 (MA-Dual Eligibles):** Medicaid and Medicare (dual) eligibles receiving hospice services, home and community-based services, or institutional care services. Individuals with Medicare are not eligible for this waiver unless they meet the conditions of MEG 3.
- **MEG 2 (MA-Medicaid Institutional):** Medicaid-only eligibles currently receiving hospice services, home and community-based services, or institutional care services.
- **MEG 3 (MA-Medicaid Only):** Medicaid-only eligibles *not* currently receiving hospice services, home and community-based services, or institutional care services.

Individuals in MEG 1 must select a Managed Medical Assistance (MMA) plan in their region. If the recipient does not select an MMA plan they will be assigned to one. Information on the MMA program can be found on the Agency’s Web site at the following link: http://ahca.myflorida.com/medicaid/statewide_mc/index.shtml.

Table 2 details the monthly total count of individuals enrolled through the MEDS-AD Waiver for this reporting period (October 1, 2014, through December 31, 2014).

Table 2	
MEDS-AD Waiver Enrollment	
October 1, 2014 – December 31, 2014	
Month	Total Enrollment*
October 2014	40,333
November 2014	40,246
December 2014	40,007

*Total enrollment counts are revised for retroactive eligibility determinations, and therefore may change from one reporting period to the next.

2. Comprehensive Medication Reviews

The comprehensive medication review focuses on the MEG 1 fee-for-service group within the MEDS-AD Waiver, as these individuals are not receiving institutional care or are served by a managed care entity. The process includes an initial direct telephone contact to a recipient from a clinical pharmacist who explains the review process and invites the recipient to participate. If the recipient agrees, a call with a case reviewer is scheduled for performance of a comprehensive medication review. A medication action plan is then developed. Quarterly follow-up reviews of the patient health information and claims history are performed to track the result of the review and feedback to the prescriber. The patient and prescriber are contacted again if issues or risks are identified.

Please see Attachment A for a detailed progress report prepared by the University of Florida (UF) providing all case review activities for the period October 1, 2014, through December 31, 2014. This report includes detail of case status, patient specific intervention results, listing of interventions faxed to prescribers, a tabulation of the results of the interventions by clinical category, and details of patient responses and ratings of the comprehensive reviews.

3. Data Mining Activities

The current status of initiatives resulting from the data mining activities approved through the MEDS-AD Waiver for the period October 1, 2014, through December 30, 2014, is as follows:

- During the time period, the Medicaid Fraud Control Unit (MFCU) opened two new complaints as a result of DMAR-018
- During the time period, MFCU converted one complaint to a case for DMAR-038
- DMAR-052 closed with no signification findings
- DMAR initiatives for this quarter have resulted in two referrals to the Agency for health care administrative action for DMAR-070
- DMAR-025 resulted in a civil settlement with a provider for \$73,883.93

IV. Evaluation Activity

1. Evaluation Requirements

The Agency has contracted with Florida State University to conduct an independent evaluation of the MTM program and data mining activities during the renewal period for the MEDS-AD Waiver (January 1, 2011 – December 31, 2014). The evaluation plan for the MEDS-AD Waiver renewal period was submitted to the Centers for Medicare and Medicaid Services (CMS) on April 29, 2011. No deficiencies were noted, and the evaluation activities are proceeding as planned.

The contract was renewed on June 12, 2014, for one year (July 1, 2014 – June 30, 2015) to cover the evaluation period for the extension of the MEDS-AD Waiver. Modifications to the contract were made to revise the methodologies used in the analyses to align with the focus and goals of year three of the contract, and to update date spans for all data needed to conduct the evaluation. Final evaluation reports are due to the Agency on February 28, 2015.

On November 21, 2014, CMS granted a temporary extension of the MEDS-AD Waiver, effective January 1, 2015, until December 31, 2015. Over the next quarter, the contract will be renewed for another year to cover the evaluation period for this waiver.

2. MEDS-AD MTM Program Description, Design, and Initial Findings

The MTM program, implemented by UF's College of Pharmacy, uses high-intensity pharmacy case management services in conjunction with access to appropriate medical care for select aged and disabled individuals as a way to maintain care in the community and prevent premature institutionalization. The program is to be budget-neutral and incorporate innovative service concepts. The Special Terms and Conditions of the MEDS-AD Waiver require that the total cost of medical services and MTM for persons who are enrolled in the MEDS-AD Waiver be compared with the estimated cost of institutional care that is avoided.

In October 2014, the vendor requested a refresh of MTM data for January 1, 2014, through May 31, 2014. The data were delivered to the vendor in December 2014, and will be used to compare participants and non-participants in Cohorts 1, 2, and 3* during the pre-intervention and intervention periods. A progress report was submitted by the research team to the Agency in October 2014, which included a summary of the current activities, updates for the upcoming quarter, and disclosure of any issues that may impact the timely submission of accurate and quality deliverables.

Health, utilization, and financial outcomes potentially influenced by the MTM intervention will continue to be examined using the latest enrollment and inpatient, outpatient, long-term care, medical, and pharmacy claim types. A preliminary report is due to the Agency in January 2015.

3. Medicaid Fraud Control Unit Evaluation Component

The goal of the data mining initiative under the MEDS-AD Waiver is to determine if data mining activities performed by the MFCU in the Florida Office of the Attorney General, in conjunction

* Cohort 1: 6/1/2011 – 5/31/2012; Cohort 2: 6/1/2012 – 5/31/2013; Cohort 3: 6/1/2013 – 5/31/2014.

with the Agency's Bureau of Medicaid Program Integrity (MPI), result in the recovery of Medicaid funds paid as a result of fraudulent or abusive billing. The evaluation of data mining activities includes literature research, key informant interviews, and MFCU and MPI case file reviews.

During this quarter, the research team submitted a preliminary evaluation of the data mining activities authorized under the MEDS-AD Waiver. The preliminary report was related to all components of the evaluation and included quantitative and qualitative analyses. A second request for data related to data mining activities, including key informant interviews, was made in October 2014. All requested data were received by the research team in December 2014. A progress report was submitted by the research team to the Agency in October 2014, which included a summary of the current activities, updates for the upcoming quarter, and disclosure of any issues that may impact the timely submission of accurate and quality deliverables.

A final evaluation report is due to the Agency by February 28, 2015.

V. Waiver History

1. Legislative Changes

In 2005, concurrent with federal Medicare Part D implementation, the Florida Legislature amended the statutory eligibility criteria for the MEDS-AD program and directed the Agency, in Chapter 2005-60, Laws of Florida, to seek federal waiver authority to revise Medicaid eligibility coverage for the Medicaid MEDS-AD eligibility group beginning January 1, 2006. The eligibility changes to the MEDS-AD program maintained eligibility for qualified recipients without Medicare coverage and eliminated coverage for dually eligible individuals unless the person is eligible for and receiving Medicaid hospice services, home and community-based services, or institutional care services.

2. Program Design

To implement the Legislative changes described above, the State amended Florida Medicaid's State Plan to eliminate the former MEDS-AD eligibility category and submitted an 1115 demonstration waiver for aged or disabled residents of the State of Florida with incomes at or below 88% of the FPL and assets at or below \$5,000 for an individual and \$6,000 for a couple. Coverage is limited to those aged and disabled persons who are either receiving or elect to receive hospice services, home and community-based services, or institutional care services or who are not eligible for Medicare. The new MEDS-AD program is designed to prevent premature institutionalization of these vulnerable individuals by maintaining their level of care in the community longer through the provision of:

- Access to health care services
- Medication therapy management

The continued coverage, as well as the MTM program, will be funded through savings obtained by avoiding institutional costs that would otherwise occur in the next five years had these vulnerable individuals been denied access to prescribed drugs and other medical services. The focus of the demonstration is to provide MTM for enrollees who are not yet receiving institutional care.

3. Waiver Extension or Phase-Out

In December 2010, the State received approval from CMS for the renewal period January 1, 2011, through December 31, 2013. On June 28, 2013, the State submitted a renewal request under 1115(a) authority to extend the MEDS-AD Waiver through December 31, 2016. The Centers for Medicare and Medicaid Services granted the State a one-year temporary extension on August 14, 2013 extending the current waiver period to December 31, 2014.

The State received a second one-year temporary extension on November 1, 2014, to extend the MEDS-AD Waiver until December 31, 2015. See Attachment B for a copy of the letter from CMS granting the second 1 year temporary extension.

4. Maintenance of Effort (MOE) Provisions in Section 1902(a)(74) and 1902(gg)

Since the MEDS-AD Waiver was renewed by CMS after March 23, 2010, it is no longer subject to the MOE provisions of the Affordable Care Act.

Attachment A
Case Review Activity Report
October 1, 2014 – December 31, 2014

Reporting for Quarter 2: October 1, 2014 to December 31, 2014

Attached Documents:

- 1. Implementation Plan** detailing the progress of each program task and identifying any current/possible barriers to the completion of identified program tasks
- 2. Quarterly Report**

Pertinent Abbreviations:

Appt = Appointment

CMR = Comprehensive Medication Review

MTMCCC = Medication Therapy Management Communication and Care Center

MAP = Medication Action Plan

1. Implementation Plan
A. Progress Report:

<i>Task</i>	<i>Entity Responsible</i>	<i>Start Date</i>	<i>Status</i>
Draft Medicaid Drug Therapy Management Program Contract	AHCA		Completed 02/24/11
Review Medicaid Drug Therapy Management Program Contract	AHCA, UFCOP MTMCCC, UF COP	02/24/11 Amended: 7/16/12	Completed
Sign Medicaid Drug Therapy Management Program Contract	UF COP		Completed 06/01/11; Amended 7/16/12 Amended 3/21/14
Draft Program Implementation Plan	UF COP MTMCCC	02/24/11	Completed
Identify Medicaid Recipients / Candidates for UF COP MTMCCC	AHCA		Completed
Transmit Identified Patients' Information to MTMCCC	AHCA	Ongoing	Completed for 2014
Develop Patient Charting System	UF COP MTMCCC	03/15/11	Completed
Develop MAP and Fax Templates	UF COP MTMCCC	03/15/11	Completed
Develop SOP/Workflow	UF COP MTMCCC	03/15/11	Completed
Train MTMCCC Staff	UF COP MTMCCC	02/23/11	Completed
Schedule CMR Appointments for Recipients/Candidates	UF COP MTMCCC	Upon receipt of patient information from AHCA	Completed for 2014
Ongoing Training of MTMCCC Staff	UF COP MTMCCC	Ongoing	Ongoing
Develop Quality Assurance Program	UF COP MTMCCC	03/31/11	Completed
Submit Documents (Program Agreements, Protocols, Educational Materials and Practice Guidelines)	UF COP MTMCCC		Completed
Approval of Documents Submitted by UF COP MTMCCC	AHCA		Completed
Develop Quarterly Reports	UF COP MTMCCC	Upon conclusion of 1 st quarter	Ongoing
Submit Quarterly Reports to AHCA	UF COP MTMCCC	No later than the 15 th of each month following the reporting quarter	Ongoing
Submit Quarterly Invoice of Services Rendered	UF COP MTMCCC	No later than the 15 th of each month following the reporting quarter	Ongoing
First Annual Survey of Sample Recipients	Non-UF Evaluator	Upon completion of required CMRs per QA program	Completed
Draft Preliminary Evaluation Report Including Survey Information	Non-UF Evaluator	Upon completion of required CMRs per QA program	Completed
Utilize Results From Surveys and Evaluation Report to Implement Corrective Action Plan	UF COP MTMCCC	As needed	Ongoing

B. Current/Possible Barriers to Task Completion Report: No barriers identified

2. Quarterly Report Data

Case Status			
Portion of the Case	Number Completed	Start Date	End Date
CMR	163	06/01/14 [^]	08/30/14
3-Month Quarterly Follow-up Review	163	9/1/2014	11/30/14
6-Month Quarterly Follow-up Review	7	12/1/2014	2/28/2015
9-Month Quarterly Follow-up Review		3/1/2015	5/31/2015

> No call activity in June 2014 due to contract negotiations with software vendor that led to contract not being renewed; administrative time needed to adjust practice model and documentation system, as well as update key documents.

Calls Made to Program Participating Patients (Including Failed Attempts)				
Intervention	Count			
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter
CMR Scheduled	203	0		
CMR Completed during Scheduling Call (Live transfer to RPh)	0	0		
Patient Interaction (Non-MTM Service Request/Inquiry)	8	0		
Patient Refused Consultation (During CMR Scheduling or CMR Call)	41	0		
Unable to Reach (Appt Scheduling) - 1st Attempt	401	0		
Unable to Reach (Appt Scheduling) - 2nd Attempt	212	0		
Unable to Reach (Appt Scheduling) - 3rd Attempt	138	0		
Unable to Reach (CMR)	0	0		
30 to 60-day CMR Check-Up	80	0		
Unable to Reach 30-60 Day CMR Check-Up*	83	0		
Quarterly Follow-Up with Encounter	0	15		

Outbound calls are made to patients initially to engage patient in the completion of the Comprehensive Medication Review (CMR). Typically appointments are scheduled and at the convenience of the patient. If the patient would like to complete the CMR call at the time of scheduling, then the call is live transferred to a pharmacist. Three call attempts (at least) are made to the patient to attempt to schedule and/or complete the CMR. Each patient receives a contact attempt again within 30 to 60 days following the CMR to determine if the patient received all of the mailed materials following the CMR. At the time of the quarterly follow-up review (QR), the patient is called only as necessary and/or when items identified during the CMR or QR require a follow-up conversation with the patient; otherwise, claims data is reviewed and a QR assessment is completed without contacting the patient.

A. Summary of Interventions ⁺

Patient Specific Interventions*				
CMR/MAP Interventions	Count			
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter
Counseled on Diet/Exercise	4	0		
Counseled on Lifestyle Modifications	19	0		
Counseled on Medication (General, side effects, indication, etc.)	149	0		
Counseled on Medication Adherence/Compliance	81	0		
Counseled on Medication Administration/Technique	10	0		
Counseled on Preventative Screenings/Vaccinations	19	0		
Counseled on Smoking Cessation	28	0		
Counseled on Weight Loss	0	0		
Educated on Asthma/COPD	29	0		
Educated on Coverage Gap	1	0		
Educated on Diabetes	46	0		
Educated on Disease State (Other)	20	0		
Educated on Dyslipidemia	2	0		
Educated on GERD	2	0		
Educated on Heart Failure	15	0		
Educated on Hypertension	39	0		
Explained MTM Program to Patient	6	0		

⁺ This data reflects initial CMRs that were performed from June 1st until August 30th, 2014.

* These include interventions that were documented during a phone conversation with the patient during a CMR well as those in the patient specific MAP. Patient specific interventions are made to patients initially during the completion of the Comprehensive Medication Review (CMR). Each patient receives a contact attempt again within 30 to 60 days following the CMR to determine if the patient received all of the mailed materials following the CMR and patient specific interventions may also be made at this time. During the quarterly follow-up review (QR), the patient is called only as necessary and/or when items identified during the CMR or QR require a follow-up conversation with the patient at which time additional patient specific interventions may be made; otherwise, claims data is reviewed and a QR assessment is completed without contacting the patient.

Provider Specific Interventions*				
Fax Intervention	Count			
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter
Adverse Drug Event Identified	7	0		
Alternative Dosage Form Recommended	0	0		
Combination Therapy Recommended (decrease pill burden)	0	0		
Duplicate Therapy Identified	1	2		
Excessive Dosage Identified	1	0		
Excessive Duration of Therapy Identified	2	0		
Excessive Pill Burden Identified (multiple tablets of lower strength)	0	0		
Gap in Therapy - Diabetic without a Statin	9	1		
Gap in Therapy - Diabetic without an ACE-I or ARB	8	0		
Gap in Therapy - Heart Failure without a Beta-Blocker	4	0		
Gap in Therapy - Heart Failure without an ACE-I or ARB	3	0		
Gap in Therapy - Lack of Controller Medication/Beta-Agonist Overuse in Asthma	5	0		
Gap in Therapy - Lack of Rescue Medication in Asthma	4	0		
Gap in Therapy - Long-Term Steroid without Anti-Resorptive Agent	2	0		
Gap in Therapy - Potentially Inappropriate Beta-Blocker Selection in Heart Failure	0	0		
Generic Alternative Recommended	0	0		
Insufficient Dosage Identified	0	0		
Insufficient Duration of Therapy Identified	0	0		
Lack of Efficacy Identified	2	0		
Lack of Therapy (Indication) Identified	7	0		
Multiple Pharmacies Identified	0	0		
Multiple Prescribers Identified	0	0		
Needs Preventative Screening / Immunizations	0	0		
Non-Adherence Issue Identified	0	0		
OTC Therapy Recommended	4	0		
Polypharmacy Identified	0	0		
Questionable Narcotic Use Identified	0	0		
Recommended Preferred Drug List Alternative	0	0		
Renal Dosing Recommended	0	0		
Unnecessary Therapy (Lack of Indication) Identified	1	0		

* These include interventions that were communicated to providers either via phone/fax.

Provider specific interventions are made to providers initially during the completion of the Comprehensive Medication Review (CMR). During the quarterly follow-up review (QR), a complete assessment of the patient's medication history takes place again typically without having to contact the patient. At the time of the QR, claims data is reviewed, problems identified during the CMR are re-assessed to see if a provider has taken any action on the previously identified issues (considered a resolved intervention), and discontinued and/or new medications are assessed to see if new problems have been created from the recent medication changes. Providers are not typically re-contacted by fax about the previously identified problem to allow sufficient time for the provider to assess the issue, determine if the issue is valid based on available data, and/or discuss the potential issue with the patient prior to adjusting therapy (potentially at the next office visit).

B. Tabulation of Interactions by Category

Interactions				
Intervention	Count*			
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter
Drug-Age Interaction Identified (Beers List)	0	0		
Drug-Allergy Interaction Identified	0	0		
Drug-Disease Interaction Identified	1	0		
Drug-Food Interaction Identified	0	0		
Drug-Pregnancy Interaction Identified	0	0		
Level 1 Clinically Significant Drug-Drug Interaction Identified	0	0		
Level 2 Clinically Significant Drug-Drug Interaction Identified	10	0		

* These include interventions that may not have been communicated to the provider depending on patient education opportunities. This particular set of interventions may include "system generated" items that may or may not be considered clinically significant, or warrant an intervention by the provider and are therefore handled directly by the pharmacist.

C. Patient Responses

Patient Response/Rating of CMR						
QA Question		Total Number of Responses	Yes		No	
			Count	%	Count	%
CMR	<i>Did you find this appointment helpful?</i>	157	145	92.36	12	7.64
	<i>Did this interview help clarify any concerns you may have had with your medications?</i>		137	87.26	20	12.74
30-60 Day Check-Up	<i>Did you find the mailed documents to be helpful?</i>	80	61	76.25	19	23.75
	<i>Did participating in the phone call increase your understanding of your medication regimen?</i>	80	72	90.00	8	10.00

D. Provider Responses

Provider Responses								
Intervention*	Identified Quarter				Resolved Quarter			Resolution Rate
	1	2	3	4	2	3	4	
Adverse Drug Event	7	0			2			
Alternative Dosage Form	0	0			0			
Combination Therapy Recommendation (decreased pill burden)	0	0			0			
Drug-Age Interaction	0	0			0			
Drug-Disease Interaction	0	0			0			
Duplicate Therapy	1	2			1			
Excessive Dosage	1	0			0			
Excessive Duration of Therapy	2	0			1			
Formulary Alternative Recommendation	0	0			0			
Gap in Therapy - Diabetic without a Statin	9	1			1			
Gap in Therapy - Diabetic without an ACE-I or ARB	8	0			3			
Gap in Therapy - Heart Failure without a Beta-Blocker	4	0			2			
Gap in Therapy - Heart Failure without an ACE-I or ARB	3	0			1			
Gap in Therapy - Lack of Controller Medication / Beta-Agonist Overuse in Asthma	5	0			1			
Gap in Therapy - Lack of Rescue Medication in Asthma	4	0			2			
Gap in Therapy - Long-Term Steroid without Anti-Resorptive Agent	2	0			1			
Gap in Therapy - Potentially Inappropriate Beta-Blocker Selection in Heart Failure	0	0			0			
Insufficient Dosage	0	0			0			
Insufficient Duration of Therapy	0	0			0			
Lack of Therapy (Indication)	7	0			1			
Lack of Efficacy	2	0			0			
Level 1 Clinically Significant Drug-Drug Interaction	0	0			0			
Level 2 Clinically Significant Drug-Drug Interaction	10	0			1			
Non-Adherence Issue	0	0			0			
Pill Burden	0	0			0			
Polypharmacy	0	0			0			
Preventative Screening / Immunizations	0	0			0			
Questionable Narcotic Use	0	0			0			
Renal Dosing Recommendation	0	0			0			
Unnecessary Therapy (Lack of Indication) Identified	1	0			0			
Total	69				17			
Year Four Program Overall Resolution Rate								24.6%

* The intervention was considered resolved when either an appropriate medication was added, discontinued, or changed that resolved the previously identified issue based on the pharmacist's recommendation.

A resolved intervention defined as: a problem that is identified by the pharmacist upon which the provider takes an action based on the pharmacist's recommendation. The problem is considered resolved once a medication change occurs for the problem identified and is confirmed by a change in prescription claims data for the patient [Ex: Gap in therapy: Diabetic patient not on a statin--Pharmacist notifies the provider that the patient is diabetic and not currently on statin therapy. The provider agrees that this information is true and prescribes a statin for the patient. The pharmacy claims system now shows a fill for a statin medication on the patient's medication profile in the pharmacy claims system. This is now considered a resolved intervention.] Resolution rate is the total number of resolved interventions divided by the total number of problems identified then multiplied by 100%. Many factors influence the resolution rate such as: the provider's actual receipt of the phone and/or facsimile communication; the provider agreeing with the pharmacist recommendation and subsequently taking action on the recommendation; the pharmacist having correct information to make an informed recommendation.

Attachment B
Temporary Extension

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-01-16
Baltimore, Maryland 21244-1850



Children and Adults Health Programs Group

NOV 21 2014

Justin Senior
Deputy Secretary for Medicaid
Florida Agency for Health Care Administration
2727 Mahan Drive, Mail Stop 8
Tallahassee, FL 32308

Dear Mr. Senior:

With this letter, the Centers for Medicare & Medicaid Services (CMS) is granting a temporary extension of Florida MEDS-AD section 1115 Demonstration (Project No. 11-W-00205/4), effective January 1, 2015 until December 31, 2015. The demonstration is currently operating under the authority of section 1115(a) of the Social Security Act. The list of waiver and expenditure authorities and Special Terms and Conditions (STCs) will continue to apply. These have been updated to reflect the revised demonstration expiration date. We have also incorporated a technical change to the expenditure authority, to accommodate the expiration of the 1915(b) Medicaid Managed Care Waiver and expansion of Medicaid managed care statewide through the Managed Medical Assistance 1115 demonstration.

CMS approval of this temporary section 1115 demonstration extension is subject to the limitations specified in the approved waiver and expenditure authorities and the list of requirements that are not applicable to the expenditure authorities. The state may deviate from the Medicaid state plan requirements only to the extent those requirements have been specifically listed as waived or not applicable to the expenditure authorities. All requirements of the Medicaid program as expressed in law, regulation, and policy statement not expressly waived or identified as not applicable shall apply to Florida's MEDS-AD program. This approval is also conditioned upon continued compliance with the enclosed STCs defining the nature, character, and extent of federal involvement in this project. Although this extension continues the expenditure authority for Medicaid Fraud Control Unit (MFCU) data mining activities, the state has other authority for these expenditures, as described in the Department of Health and Human Services final rule issued May 17, 2013 (78 FR 29055-29061). We expect that the state will continue with these activities, will claim its expenditures as permitted under that final rule, and will ensure that no duplicate claiming will occur.

These approvals are conditioned upon written acceptance from the state that it agrees with the amendments, expenditure authorities, and STCs. This written acceptance is needed for our records within 30 days of the date of this letter.

Page 2 – Mr. Senior

Your project officer is Ms. Heather Hostetler. Ms. Hostetler's contact information is as follows:


Centers for Medicare & Medicaid Services
Center for Medicaid & CHIP Services
Division of State Demonstrations and Waivers
7500 Security Boulevard
Mail Stop: S2-01-16
Baltimore, MD 21244-1850
Telephone: (410) 786-4515
Facsimile: (410) 786-8534
E-mail: Heather.Hostetler@cms.hhs.gov

Official communications regarding program matters should be sent simultaneously to Ms. Hostetler and to Ms. Jackie Glaze, Associate Regional Administrator in our Atlanta Regional Office. Ms. Glaze's address is:

Jackie Glaze
Centers for Medicare & Medicaid Services
Atlanta Federal Center, 4th Floor
61 Forsyth Street, SW Suite 4T20
Atlanta, GA 30303-8909
Telephone: (404) 562-7417
E-mail: Jackie.Glaze@cms.hhs.gov

We look forward to continued discussions with you regarding the future of the MEDS-AD demonstration.

Sincerely,



Eliot Fishman
Director

Enclosures

cc: Jackie Glaze, Associate Regional Administrator, Region IV